肺结核患者利福喷丁血药浓度监测研究  

Therapeutic drug monitoring of rifapentine in pulmonary tuberculosis patients

作　　者：彭明丽[1] 陈明[1] 温筱煦[1] 赵冠人[1] PENG Ming-li;CHEN Ming;WEN Xiao-xu;ZHAO Guan-ren(Department of Pharmacy,the 309th Hospital of PLA,Beijing 100091,China)

机构地区：[1]解放军第309医院药剂科,北京100091

出　　处：《中国药物应用与监测》2018年第2期81-84,共4页Chinese Journal of Drug Application and Monitoring

基　　金：2014年"首都临床特色应用研究"专项资助(Z141107002514023);2017年临床药学研究项目(北京药学会)

摘　　要：目的:探讨对于肺结核患者应用利福喷丁进行治疗药物监测的临床必要性。方法:采用HPLC-MS/MS法测定血浆中利福喷丁的浓度,对2016年7月–2017年3月期间67例肺结核患者血浆利福喷丁浓度进行分析。分析柱:Agilent Poroshell120SB C_(18)柱(4.6 mm×50 mm,2.7μm);保护柱:ZORBAX SB C_(18)柱(2.1 mm×12.5 mm,5μm);流动相:甲醇-0.2%醋酸溶液;流速:0.5 m L·min^(-1);梯度洗脱:0.01~3.00 min,25%甲醇;3.01~7.00 min,80%甲醇;7.01~10.00 min,25%甲醇。结果:利福喷丁在0.60~30.00μg·m L^(-1)内线性关系良好(r=0.996 2),平均回收率均>90%,RSD均<5%。患者利福喷丁峰浓度分布在1.59~39.79μg·m L^(-1)。在同样给药剂量下,利福喷丁血药浓度的个体差异较大。结论:对利福喷丁进行治疗药物监测具有重要的临床价值。Objective:To investigate the clinical necessity of therapeutic drug monitoring(TDM)of rifapentine.Methods:The concentrations of rifapentine were determined by HPLC-MS/MS.The plasma concentrations of rifapentine in 67 pulmonary tuberculosis patients from July 2016 to March 2017 were analyzed.The analysis was carried on the Agilent Poroshell 120SB C18 column(4.6 mm×50 mm,2.7μm),ZORBAX SB C18 column(2.1 mm×12.5 mm,5μm)was used as protection column.The mobile phase was consisted of methanol and 0.2%glacial acetic acid.The flow rate was 0.5 mL·min-1.The gradient elution was as follows:0.01– 3.00 min,25%methanol;3.01– 7.00 min,80%methanol;7.01– 10.00 min,25%methanol.Results:The linear range of rifapentine was 0.60– 30.00μg·mL-1(r=0.996 2).The average recovery was above 90%with RSD below 5%.The peak concentrations of rifapentine were ranged from 1.59μg·mL-1 to 39.79μg·mL-1.The concentration of rifapentine showed obviously individual difference.Conclusion:There was a definite clinical value for therapeutic drug monitoring of rifapentine.

关 键 词：利福喷丁 肺结核 血药浓度 高效液相色谱-质谱联用法 

分 类 号：R917[医药卫生—药物分析学]